SCHEMBL7420446

SCHEMBL7420446

CCCCOc1ccc(S(=O)(=O)NCC(C)CC(=O)NO)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 10/20 0.70
MMP2 P08253 6/20 0.70
MMP13 P45452 4/20 0.70
MMP14 P50281 3/20 0.70
ADAMTS4 O75173 1/20 0.70
ADAMTS5 Q9UNA0 1/20 0.70
MMP3 P08254 6/20 0.56
MMP9 P14780 3/20 0.52
MMP8 P22894 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 1/20 0.51
KDM4E B2RXH2 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
PDE4A P27815 1/20 0.50
HIF1A Q16665 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC1 Q13547 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108648 0.88 MMP1 (0.70) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL7413723 0.85 MEP1B (0.62) MMP1MMP2MMP13MMP3MMP9
SCHEMBL7411095 0.83 MMP1 (0.65) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL7414039 0.82 MMP1 (1.00) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL6323746 0.81 MMP1 (0.61) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL7419693 0.81 HDAC8 (0.48) MMP1MMP2MMP13MMP14MMP3
SCHEMBL7417307 0.80 MMP1 (0.76) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL7464069 0.80 MMP1 (0.64) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL6320849 0.78 ADAMTS4 (0.58) MMP1MMP2MMP13MMP14ADAMTS4
SCHEMBL7487250 0.77 MMP1 (0.60) MMP1MMP2MMP13MMP14ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed